A prospective longitudinal survey of erectile function status in symptomatic benign prostatic hyperplasia patients treated with dutasteride.

about

A prospective longitudinal survey of erectile function status in symptomatic benign prostatic hyperplasia patients treated with dutasteride.

Item

http://www.wikidata.org/entity/Q48851200

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

A prospective longitudinal sur ...... ents treated with dutasteride.

@en

A prospective longitudinal sur ...... ents treated with dutasteride.

@nl

type

Item

label

A prospective longitudinal sur ...... ents treated with dutasteride.

@en

A prospective longitudinal sur ...... ents treated with dutasteride.

@nl

prefLabel

A prospective longitudinal sur ...... ents treated with dutasteride.

@en

A prospective longitudinal sur ...... ents treated with dutasteride.

@nl

P1476

A prospective longitudinal sur ...... ents treated with dutasteride.

@en

P2093

Akira Miyajima

http://www.w3.org/2001/XMLSchema#string

Kazuyuki Yuge

http://www.w3.org/2001/XMLSchema#string

Masanori Hasegawa

http://www.w3.org/2001/XMLSchema#string

Masashi Matsushima

http://www.w3.org/2001/XMLSchema#string

Mototsugu Oya

http://www.w3.org/2001/XMLSchema#string

Takahiro Maeda

http://www.w3.org/2001/XMLSchema#string

Toshiyuki Ando

http://www.w3.org/2001/XMLSchema#string

Yujiro Ito

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.

Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients.

Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo.

Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.

Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia.

EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.

Effects of the 5 alpha-reductase inhibitor finasteride on serum levels of gonadal, adrenal, and hypophyseal hormones and its clinical significance: a prospective clinical study.

Erectile dysfunction after therapy with metoprolol: the Hawthorne effect.

The nocebo effect and its relevance for clinical practice.

Changes in sexual function in benign prostatic hyperplasia patients taking dutasteride: 1-year follow-up results.

P304

111-116

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/13685538.2016.1156082

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Eiji Kikuchi

P577

2016-03-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26964647

http://www.w3.org/2001/XMLSchema#string